Cerundolo V
Institute of Molecular Medicine Nuffield Department of Medicine Oxford, OX3 9DS, UK.
Curr Biol. 1999 Sep 23;9(18):R695-7. doi: 10.1016/s0960-9822(99)80442-4.
Recent studies have identified new melanoma antigens that are recognised by CD4(+) T cells. Analysis of tumour-specific CD4(+) T-cell responses may lead to the development of optimal anti-cancer vaccines that can induce an orchestrated effort of tumour-specific CD4(+) and CD8(+) T cells in the fight against cancer.
最近的研究已经鉴定出了可被CD4(+) T细胞识别的新型黑色素瘤抗原。对肿瘤特异性CD4(+) T细胞反应的分析可能会促使开发出最佳的抗癌疫苗,这种疫苗能够在对抗癌症的过程中诱导肿瘤特异性CD4(+)和CD8(+) T细胞协同发挥作用。